Ipca laboratories has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory certificate with both BSE and National Stock Exchange of India Limited on April 8, 2026.

Regulatory Compliance Filing

The certificate was submitted in compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Corporate Counsel & Company Secretary Harish P. Kamath digitally signed and filed the document on behalf of Ipca Laboratories Limited.

Registrar Confirmation Certificate

The filing includes a confirmation certificate dated April 3, 2026, from MUFG Intime India Pvt. Ltd. (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. The certificate confirms compliance with securities dematerialisation processes during the quarter.

MUFG Intime India confirmed that:

• Securities received from depository participants for dematerialisation during Q4FY26 were properly confirmed to depositories
• Security certificates received for dematerialisation were confirmed or rejected within prescribed timelines
• Security certificates were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners

Certificate Authentication

The confirmation certificate was issued by Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India Private Limited. The document was addressed to Ipca Laboratories' Compliance Officer and Company Secretary at the company's registered office in Kandivli Industrial Estate, Mumbai.

This quarterly filing demonstrates Ipca Laboratories' adherence to SEBI's regulatory requirements for listed companies regarding depositories and participant regulations.

Ipca Laboratories Limited has issued a newspaper notice regarding the re-lodgement of a transfer request for physical shares, in compliance with SEBI regulations. The pharmaceutical company filed this notice with BSE Limited and National Stock Exchange of India Limited on April 2, 2026, as mandated under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Share Transfer Details

The transfer request involves securities originally held by Sunil Patel, which are being claimed by Ms. Neha Varshini Patel. According to the company's notice, Ms. Neha Varshini Patel, residing at 1, Ambica Society, Umratnagar, Ahmedabad-380013, has submitted the required documentation including the share certificate and old share transfer form.

Regulatory Compliance Process

The notice follows SEBI Circular SEBI/HO/MIRSD/DOES/CR/R/2018/139 dated November 6, 2018, and SEBI Circular SEBI/HO/MIRSD/MIRSD/CR/P/CR/2025/87 dated July 2, 2025. These regulations govern the transfer of physical shares and require companies to publish public notices for such transactions.

Ms. Neha Varshini Patel has claimed that the securities were gifted to her but could not be transferred to her name earlier. The company noted that the face value of equity shares has since been sub-divided from Rs.10/- to Rs.1/- each.

Claims and Timeline

Ipca Laboratories has established a 30-day period from the date of publication for any person with claims regarding the mentioned securities. Claimants must lodge their claims at the company's registered office along with appropriate documentary evidence. The company has warned that if no valid claims are received within this timeframe, it will proceed to transfer the securities to Ms. Neha Varshini Patel and issue the necessary entitlement letter without further intimation.

Corporate Communication

The notice was signed by Harish P. Kamath, Corporate Counsel & Company Secretary of Ipca Laboratories Limited. The communication was filed through online filing and published in Business Standard and Navshakti newspapers as required by regulatory guidelines. This transparent process ensures compliance with SEBI's disclosure requirements while protecting the interests of all stakeholders involved in the share transfer process.